



## **GvHGvL 2024**

**Programmkomitee: D Weber, D Wolff, M Edinger, H Poeck, W Herr, HJ Kolb, E Holler**

**Preliminary program Feb 5, 2024**

**Wednesday, March 13, 2024**

**1.00 – 1.10pm: Welcome - W Herr, E Holler**

**1.10 – 3.15. pm Session I**

**A and cGvHD Pathophysiology (Chairs R Zeiser, O Penack)**

1.10-1.35 P Reddy: Tissue tolerance

1.35-2.00 E Meedt: A delicate balance of Tregs and alloreactive clonal CD8 cells in intestinal biopsies

2.00-2.25 C Wright: Single cell analysis of cutaneous aGvHD

2.25—2.50 A Hanash: IL22/IL33 in GvHD

2.50-3.15 RJ Chakraverty: T cell autoimmunity and cGvHD

**3.15-3.45 pm**

**Coffee Break**

**3.45-4.15 pm**

**Keynote Lecture (Chair W Herr, E Holler) : M v d Brink –CAR-T and allogeneic SCT – where do we go**

**4.15- 5.55 Session II**

**Acute and cGvHD: Biomarkers (Chairs: M Bornhäuser, F Berberich-Siebelt)**

4.15-4.40 T Winkler: Early expansions of IgA plasmablasts as predictors for chronic GvHD

4.40-5.05 G Socie: Can multiomics be the path to biomarker discovery?

5.05-5.30 J Levine: MAGIC 2024

5.30-5.55 K Schultz: Results of the ABEL consortium on biomarkers of cGvHD

5.55 – 6.30 Break: Beer and Brezel

**6.30 – 7.30 pm:**

**Evening discussion/session: Focus on GvHD**

**Thursday, March 14, 2024**

**8.30 – 10.35 Session III**

**Microbiota and beyond: Where do we go (Chairs: Andre Gessner, K Hildner)**

8.30-8.55 R Jenq: Microbiome remediation therapies to reduce SCT toxicities

8.55-9.20 D Weber: MAGIC biomarkers and microbiota

9.20-9.45 E Orberg: Multiomic approach and transkingdom interaction

9.45-10.10 H Poeck: Metabolites dampening GvH and promoting GvL

10.10-10.35 A Beilhack: Microbiota and induction of GvHD by early inflammatory events

**10.35 – 11.00 Coffe break**

**11.00 – 12.40 Session IV**

**GvHD: New options for prophylaxis and treatment (Chairs: H Greinix, M Edinger)**

11.00-11.25 J Ferrara: Inhibition of RIP1 to modulate GvH and GvL

11.25-11.50 Y.Floisand: Vedolizumab prophylaxis

11.50-12.15 R.Zeiser: GLP2 Agonists

12.15-12.40 J Schetelig – ATG vs PostTxCy

**12.40 – 13.45: Lunch Break**

**13.45 – 15.05 Session IV**

**Regulatory T cells (Chairs: P Hoffmann, D Schneidawind)**

**13.45-14.15 Keynote Lecture by E Meyer: Orca T – update on a new hope for patients**

14.15-14.40 M Edinger: Pathophysiology and experimental data

14.40-15.05 M Feuerer: Update on and strategies with Tissue T regs

**15.05 – 15.30: Coffee Break**

**15.30 – 17.35 Session V**

**T cell biology/ Graft-versus-Leukemia I (Chairs G Willimski, H Einsele)**

15.30-15.55 L Hansmann: Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

15.55-16.20 M Heemskerk: New strategies against minor antigens

16.20-16.45 E Ullrich: NK /engineered NK cells and GvL

16.45-17.10 J DiPersio: Local HLA upregulation by T cell immunotherapies to improve GvL

17.10-17.35 D Mougiakakos: Oxydative stress and GvL following allogeneic SCT

**18.30 Social evening**

**Friday, March 15, 2024:**

**9.00 – 9.30: Session VI**

**HJ Kolb award and lecture (Chair HJ Kolb)**

**9.30 -11.10 Session VII**

**CAR-T cells/GvL II – focus on myeloid malignancies (Chair S Thomas, A Mackensen)**

9.30-9.55 L Gattinoni: Enhancing GVL responses by donor-derived CAR-modified CD8+ T memory stem cells

9.55-10.20 K Schober: TCRs against immunodominant antigens in AML

10.20-10.45 M Hudecek: One fits for all: Upgrade on targets and technologies for CAR-T cells in AML

10.45-11.10 E Ruggieri: T cell exhaustion in AML

**11.10 – 11.40 Coffee Break**

**11.40 - 12.55 Session VIII .**

**CAR-T cells/GvL -III (Chairs H Abken, Ph Beckhove)**

11.40-12.05 D Harrer: CAR-T and type 1 interferon release

12.05-12.30 K Fleischhauer: Exploiting HLA disparity for GvL

12.30-12.55 L Vago: Leukemia Immune Escape after Transplant: from Biology to Precision Medicine (and Back)

**12.55 – 13.00 Closure**

**13.00-14.00 Farewell Lunch**